Drug Trial Radar · NCT07623707
A Study of FG-B901 Monotherapy or Combination With Chemotherapy in Advanced or Metastatic Solid Tumors
Last checked: Nov 19, 2026Latest source record: Jun 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
264
Planned (sponsor's estimate)
Start
Jul 2026
Primary completion
Dec 2027
Study completion Jul 2029
Sponsor
- Lead sponsor
- FutureGen Biopharmaceutical (Beijing) Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Jun 3, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
FG-B901 is a recombinant humanized IgG2 bispecific antibody targeting PD-L1 and CD40. It is designed to provide PD-L1-dependent CD40 agonism, thereby enhancing selectivity for the tumor microenvironment and reducing systemic toxicity compared with conventional CD40 agonists. Preclinically, FG-B901 promotes antigen-presenting cell activation and synergizes with PD-L1/PD-1 blockade to potentiate T-cell anti-tumor immunity. This is an open-label, multicenter phase I/II trial in subjects with unresectable locally advanced or metastatic solid tumors. The primary objectives are to evaluate the safety, tolerability, and pharmacokinetics of FG-B901 as monotherapy and in combination with chemotherapy. Secondary objectives include preliminary anti-tumor efficacy (e.g., objective response rate, disease control rate, progression-free survival, and overall survival).
Conditions
- Solid Tumor
Interventions
FG-B901Drug
Accelerated titration method, IV infusion Q3W; Adaptive BOIN design, IV infusion Q3W. (21-day cycles)
standard or investigator-determined chemotherapyDrug
standard or investigator-determined chemotherapy depending on the type of tumors.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety assessed by Adverse Events (AEs)Time frame: Up to 24 months
- Maximum Tolerated Dose (MTD)Time frame: 21 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Fudan University Shanghai Cancer Center
Shanghai, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.